



Date: 18th December, 2025

To,
BSE Limited
Listing Department
Phiroze Jeejeebhoy Towers,
Dalal street- Fort
Mumbai-40001.

Scrip Code: 539730

Subject: Corrigendum through General Announcement regarding disclosure of Pre-Preferential Shareholding of Proposed Allottees, Ultimate Beneficial Owners (UBOs), Revised Issue Size of Proposed Preferential Allotment, Revised List of Allottees and Bifurcation and Brief description of the object of the issue in connection with the Extra-Ordinary General Meeting (EGM) held on October 22, 2025.

Dear Sir/ Madam,

With reference to the Notice of the Extra-Ordinary General Meeting ("EGM") of Fredun Pharmaceuticals Limited ("the Company") dated September 30, 2025, the Corrigendum to the EGM Notice dated October 17, 2025, and the resolutions passed at the EGM held on October 22, 2025 relating to the preferential issue of Equity Shares and Warrants, the Company hereby issues this general announcement to ensure full transparency and compliance.

The Company is providing a consolidated and updated statement of:

- (i) the pre-preferential shareholding of all proposed allottees,
- (ii) the Ultimate Beneficial Owners (UBOs) of the proposed allottees, wherever applicable /required,
- (iii) the particulars of the proposed preferential issue
- (iv) the list of allottees and
- (v) Bifurcation and Brief description of the object of the issue, - attached as "Annexure A"





i) Details of pre-preferential shareholding of the allottees:

Name of the Allottee	Pre-preferential shareholding (No. of shares)	Whether pre-preferential shareholding in physical/ demat	Lock in Details		Pledge Details	
			Date From	Date To	No of shares	Name of institution
Fredun Nariman Medhora	1,79,672	Demat	01-10-2025	31-05-2026	NA	
Daulat Nariman Medhora	14,10,898	Demat	01-10-2025	31-05-2026	NA	
Nikhil Ramesh Jaisinghani	18	Demat	02-10-2025 (11 Shares)	31-05-2026	NA	
			18-12-2025 (7 Shares)	31-05-2026		
Prithviramac handra Vashist	4,530	Demat	01-10-2025 (880 Shares)	31-05-2026	NA	
			18-12-2025 (3,650 Shares)	31-05-2026		
Tanvi Achariya	6,608	Demat	02-10-2025	31-05-2026	NA	





CIN No.: L24239MH1987PLC043662

Patel Janki Siddharth	237	Demat	17-12-2025	31-05-2026	
M/s. Gunchandra C Mehta HUF	10	Demat	16-10-2025	31-05-2026	NA
Vivek Dhir	3,750	Demat	18-12-2025	31-05-2026	NA
TOTAL	16,05,723				

ii) The revised consolidated lists of the proposed allottees along with their respective UBO details are as follows:

Sr. No.	Name of the proposed allottees	Name of the UBO	PAN of the UBO
1	Alchemy Capital Management Pvt Ltd	Mr. Lashit Lallubhai Sanghvi	AAHPS6774J
		Mr. Ashwin Kedia	ACGPK7677P
		Mrs. Rekha Jhunjunwala, Principal executor on behalf of "Estate of Late Shri. Rakesh Jhunjunwala")	AAEPJ2191B
2	R R Family Trust	Mr. Ramesh Thakurdas Jaisinghani	AACPJ2100L
		Ms. Reina Ramesh Jaisinghani	ADUPJ4939L
3	Priyabhakta Commotrade Private Limited	Mr. Akhilesh Saraogi	AMAPS1312B
		Ms. Shruti Saraogi	ATYPS2728Q
4	Somani Stock Broking Pvt Ltd	Mr. Rajesh Kumar Somani	AJMPS2279N
		Mr. Rakesh Somani	AJMPS2281G
		Ms. Sushila Somani	AJJPS2451D
5	Aryavrat Financial Services Private Limited	Mr. Raj Kumar Agarwal	ACKPA0021B
6	Sona Vets Private Limited	Mr. Sameer Agarwal	ACQPA9823M
7	NAV Capital VCC-NAV Capital Emerging Star Fund	Mr. Veerendra Kedarnath Chandalada	ADCPC4142Q
8	Nav Bharat Investment Trust- Nav Bharat Investment Opportunities Fund	Mr. Ravindra Dutt Tyagi	ABXPT5951F
		Mr. Anita Tyagi	ACZPT0074E
		Mr. Vineet Arora	ACJPA6994L
		Mr. Jatin Agarwal	BWBPA9131Q
9	H&A Ventures (On behalf of	Ms. Priyanka Himanshu Jain	BFYPM1771E





	Shipra Bhutra)	Ms. Shipra Abhishek Bhutra	BJPPB6877F
10	Capri Global Holdings Private Limited	Mr. Rajesh Sharma	AMBPS1495A
11	Dhananjay Advisors (On behalf of Ritu Rani)	Ms. Ritu Rani	AJFPR6068P
12	Instanow Info Systems Private Limited	Mr. Pramod Agarwal	AGMPA0693H
		Mr. Mahesh Kumar	ATGPK1597F
		Mr. Mohit	AZIPM3804D
		Mr. Deepak Kumar	BTAPD2948E
		Mr. Aryan Tyagi	BINPT0384A
13	Rajesh Suryakant Gandhi (HUF)	Mr. Rajesh Suryakant Gandhi	ADZPG2163J
14	Czar Capital Private Limited	Mrs. Sonal Kothari	BOOPK2624B
		Ms. Sejal Jhaveri	AHZPJ9699N
15	Hiten B Shah HUF	Mr. Hiten B Shah	AADPS7814B
16	Ceramet Consultants Private Limited	Mr. Aniket Gore	ADHPG1568M
17	Shagun Capital Venture (On behalf of Shankesh Vijaykumar and Manav Vijaykumar)	Mr. Shankesh Vijaykumar	LKNPS0492N
		Mr. Manav Vijaykumar	CEEPV1801C
18	Gunchandra C. Mehta HUF	Mr. Amit Mehta	AAFPM4855J

(iii) the revised particulars of the proposed preferential issue

I) Company details:

Name of the Company	Fredun Pharmaceuticals Limited
Scrip Code	539730
ISIN No.	INE194R01017
Face Value of the equity shares of the company	Rs.10/-
Authorized Capital of the Company (Rs.)	10,00,00,000
Nominal value of the equity share capital (Rs.)	4,72,16,620
Paid up equity share capital of the Company (Rs.)	4,72,16,620
Maximum no. of shares that may be issued (inclusive of convertible instruments) pursuant to the proposed preferential issue	6,44,360 Equity Shares to Non-Promoters for Cash.





	3,51,600 Convertible Warrants to Non-Promoters for Cash. 2,00,000 Convertible Warrants to Promoter and Promoter Group for Cash.
Paid up equity share capital of the Company post proposed issue on fully diluted basis (Rs.)	5,91,76,220

II) Issue details:

Details of security proposed to be issued			
	Promoters	Non-promoters	Total
Equity (Nos.)	-	6,44,360	6,44,360
Warrants (Nos.)	2,00,000	3,51,600	5,51,600
Others (PCD/FCD, preference shares, etc) (Nos.)	-	-	-
In case of convertible instrument, period when the same can be exercised/ converted	Within 18 months from the date of allotment	Within 18 months from the date of allotment	





(iv) the revised list of allottees

Name of the Proposed Allottee	Category (Promoter/ Non - Promoter)	Permanent Account Number (PAN)	No. of securities to be allotted		Allottee is: *QIB/ Non QIB	Post issue % of capital that allottee will hold
			Equity	Warrants		
Fredun Nariman Medhora	Promoter	AKRPM6247L	-	1,60,000	Non QIB	5.74%
Daulat Nariman Medhora	Promoter	AABPH1066J	-	40,000	Non QIB	24.51%
Alchemy Capital Management Pvt Ltd	Non-Promoter	AACCA0237E	36,000	24,000	Non QIB	1.013%
Alchemy Long Term Ventures Fund, Series 2	Non-Promoter	AALTA6513H	48,000	32,000	Non QIB	1.351%
Neha Lashit Sanghvi	Non-Promoter	ABWPS9204P	36,000	24,000	Non QIB	1.013%
Karthik Sundar	Non-Promoter	AAZPI2661N	24,000	16,000	Non QIB	0.675%
Shruthi M	Non-Promoter	AXNPM8152H	14,400	9,600	Non QIB	0.405%



FREDUN PHARMACEUTICALS LIMITED

Compassionate Healthcare

CIN No : L24239MH1987PLC043662



Vanaja Sundar Iyer	Non-Promoter	AAGPI2464J	48,000	32,000	Non QIB	1.351%
Nikhil Ramesh Jaisinghani	Non-Promoter	AHYPJ2714R	24,000	16,000	Non QIB	0.676%
Girdhari Thakurdas Jaisinghani	Non-Promoter	AAAPJ8473A	24,000	16,000	Non QIB	0.675%
Reshma Manish Kukreja	Non-Promoter	AJFPK8842G	1200	800	Non QIB	0.033%
Juhi Hemant Ramani	Non-Promoter	AAIPJ7536J	1200	800	Non QIB	0.033%
Karina C Moriani	Non-Promoter	AAAPJ8472B	1200	800	Non QIB	0.033%
R R Family Trust	Non-Promoter	AAETR5355B	20,400	13,600	Non QIB	0.574%
Ajay Kumar Aggarwal	Non-Promoter	AANPA0334J	48,000	32,000	Non QIB	1.351%
Ujiyara Sarees Private Limited	Non-Promoter	AABCU4124H	4,000	-	Non QIB	0.067%
Priyabhakta Commotrade Private Limited	Non-Promoter	AAMCP2941C	2,000	-	Non QIB	0.033%
Mohak Rajesh Gupta	Non-Promoter	AMBPG3779M	4,000	-	Non QIB	0.067%

Registered Office: Urmi Estate, 11th Floor, Ganpatrao Kadam Marg, Lower Parel (W), Mumbai - 400013.

Phone No.: 91-22- 4031 8111 Fax: 91-22-4031 8133

Factory: 14,15,16, Zorabian Industrial Complex, Vevoor, Palghar (E), Dist: Palghar - 401 404.

Phone No.: +917045957828, +917045957829, +917045957830, +917045956857

E-Mail: business@fredungroup.com Web: www.fredungroup.com



FREDUN PHARMACEUTICALS LIMITED

Compassionate Healthcare

CIN No : L24239MH1987PLC043662



Pulak Patodia	Non-Promoter	AFTPP0023L	2,000	-	Non QIB	0.033%
Vrinda Patodia	Non-Promoter	ACLPP6507C	2,000	-	Non QIB	0.033%
Somani Stock Broking Pvt Ltd	Non-Promoter	AADCS8388P	4,000	-	Non QIB	0.067%
Aryavrat Financial Services Private Limited	Non-Promoter	AACCA5579M	2,000	-	Non QIB	0.033%
Sona Vets Private Limited	Non-Promoter	AAECS0908G	8,000	-	Non QIB	0.135%
NAV Capital VCC-NAV Capital Emerging Star Fund	Non-Promoter	AAICN2612C	56,000	-	Non QIB	0.946%
NavBharat Investment Trust-NavBharat Investment Opportunities Fund	Non-Promoter	AAETN5775B	24,000	-	Non QIB	0.405%
H&A Ventures	Non-	AAQFH7269A	2,000	-	Non QIB	0.033%

Registered Office: Urmi Estate, 11th Floor, Ganpatrao Kadam Marg, Lower Parel (W), Mumbai - 400013.

Phone No.: 91-22- 4031 8111 Fax: 91-22-4031 8133

Factory: 14,15,16, Zorabian Industrial Complex, Vevoor, Palghar (E), Dist: Palghar - 401 404.

Phone No.: +917045957828, +917045957829, +917045957830, +917045956857

E-Mail: business@fredungroup.com Web: www.fredungroup.com





	Promoter					
Capri Global Holdings Private Limited	Non-Promoter	AABCM4155A	80,000	-	Non QIB	1.351%
Dhiren Mahendrakumar Shah	Non-Promoter	BEEPS4980Q	16,000	-	Non QIB	0.270%
Harish Sitaram Sharma	Non-Promoter	AMGPS0035F	4,000	-	Non QIB	0.067%
Sanjay Sinha	Non-Promoter	AIQPS7061K	800	-	Non QIB	0.013%
Sachin Gupta	Non-Promoter	APVPG8824N	4,000	-	Non QIB	0.067%
Patel Janki Siddharth	Non-Promoter	BELPC3234G	2,000	-	Non QIB	0.037%
Kedar Ramesh Deshpande	Non-Promoter	AAMPD7153P	8,000	-	Non QIB	0.135%
Prithviramachandra Vashist	Non-Promoter	ADYPV4537G	2,000	-	Non QIB	0.110%
Instanow Info Systems Private Limited	Non-Promoter	AAGCI8747M	8,160	-	Non QIB	0.137%





Rajesh Suryakant Gandhi (HUF)	Non-Promoter	AAQHR5171P	2,400	-	Non QIB	0.040%
Archana Kapur	Non-Promoter	AARPK0112G	2,000	-	Non QIB	0.033%
Tanvi Achariya	Non-Promoter	AXMPA8236B	8,000	-	Non QIB	0.246%
Himanshu Sureshchandra Shah	Non-Promoter	BBOPS1540P	32,000	-	Non QIB	0.540%
Nimisha Amit Kothari	Non-Promoter	AGQPK3902R	4,000	-	Non QIB	0.067%
Dhiren Chandulal Shah	Non-Promoter	AAGPS6972B	11,600	-	Non QIB	0.196%
Czar Capital Private Limited	Non-Promoter	AAGCC3019E	2,000	-	Non QIB	0.033%
Hiten B Shah HUF	Non-Promoter	AABHH1074C	6,000	-	Non QIB	0.101%
Jeel hiten Shah	Non-Promoter	HAQPS3482D	3,000	-	Non QIB	0.050%
Gajjar Anuradha Himansu	Non-Promoter	AGOPH0335F	12,000	-	Non QIB	0.202%



FREDUN PHARMACEUTICALS LIMITED

Compassionate Healthcare

CIN No : L24239MH1987PLC043662



Divya Aggarwal	Non-Promoter	BAGPA0154E	-	8,000	Non QIB	0.135%
Niharika Aggarwal	Non-Promoter	BJLPA3304G	-	2,000	Non QIB	0.033%
Sahil Dhir	Non-Promoter	GMDPD8061B	-	4,000	Non QIB	0.067%
Rinkle Jain	Non-Promoter	AFCPD5682E	-	4,000	Non QIB	0.067%
Rashmi Jain	Non-Promoter	AEKPJ6735P	-	4,000	Non QIB	0.067%
Sweta Chokhany	Non-Promoter	ALBPS0713J	-	4,000	Non QIB	0.067%
Vartika Chokhany	Non-Promoter	AFAPC5089G	-	4,000	Non QIB	0.067%
Vivek Dhir	Non-Promoter	ADDPD6679E	-	8,000	Non QIB	0.198%
Divya Arora	Non-Promoter	BAGPA0154E	-	24,000	Non QIB	0.405%
Jinendra G	Non-Promoter	DQXPG5715A	-	20,000	Non QIB	0.337%
Shagun Capital Venture (On behalf of Shankesh Vijaykumar and Manav Vijaykumar)	Non-Promoter	AEWFS6331Q	-	4,000	Non QIB	0.067%

Registered Office: Urmi Estate, 11th Floor, Ganpatrao Kadam Marg, Lower Parel (W), Mumbai - 400013.

Phone No.: 91-22- 4031 8111 Fax: 91-22-4031 8133

Factory: 14,15,16, Zorabian Industrial Complex, Vevoor, Palghar (E), Dist: Palghar - 401 404.

Phone No.: +917045957828, +917045957829, +917045957830, +917045956857

E-Mail: business@fredungroup.com Web: www.fredungroup.com





Ceramet Consultants Private Limited	Non-Promoter	AABCC9036G	-	4,000	Non QIB	0.067%
Nav Ratan Bhaiya	Non-Promoter	AMCPB4642F	-	4,000	Non QIB	0.067%
Prithish Garg	Non-Promoter	DWVPG7926R	-	8,000	Non QIB	0.135%
Indu Golecha	Non-Promoter	AAAPI6737L	-	8,000	Non QIB	0.135%
M/s. Gunchandra C Mehta HUF	Non-Promoter	AABHM0539H	-	16,000	Non QIB	0.270%
Swati Goel	Non-Promoter	AMUPJ7776Q	-	8,000	Non QIB	0.135%

The above details supersede any disclosures regarding Proposed Issue Size, List of allottees, Pre preferential holdings of proposed allottees and UBOs in the earlier communications (Notice of EGM and Corrigendum dated October 17, 2025) and shall be read in conjunction with the original terms and conditions set out in the Notice of the EGM.

We confirm that this clarification does not change the nature, terms, or conditions of the proposed allotment, the resolutions passed, or the rights/obligations of any stakeholder.

Kindly take the above on record.

Thanking You,
Yours faithfully,

FOR FREDUN PHARMACEUTICALS LIMITED

FREDUN MEDHORA
MANAGING DIRECTOR AND CFO
DIN: 01745348

PLACE: MUMBAI



ANNEXURE A

Utilisation of Funds

Sr.No	Particulars	Total estimated amount to be utilised for each of the Objects (₹ in Crores)	Tentative Timeline for Utilization of Issue Proceeds from the date of receipt of funds	Reason for providing broad range for estimated amount to be utilised
1	Brand Marketing & Distribution	49-53	12 to 24 months	The estimated expenditure may vary based on market conditions, campaign scale, media mix, and distribution expansion requirements across regions.
2	CAPEX	6-7	9 to 12 months	The variation arises due to potential changes in vendor quotations, equipment specifications, installation costs, and project execution timelines.
3	Formulation Development & R&D	7-8	12 to 18 months	The R&D-related costs may fluctuate depending on trial outcomes, raw material pricing, regulatory requirements, and the need for additional testing or modifications.

4	Strategic & Statutory Reserves	22-25	18 to 24 months	A broad range is provided considering possible regulatory changes, future strategic requirements, and reserve adequacy assessments based on evolving business needs.
5	Contingency / Miscellaneous	7-8	6 to 9 months	The contingency amount is indicative as it covers unforeseen expenses, market volatility, and cost escalations that may arise during project execution.
6	Working Capital	53-59	12 to 18 months	Working capital requirements may vary owing to fluctuations in operating cycles, inventory levels, credit terms, and overall business volume.
	Total	153.25		

Business Expansion Brief – Integrated Health, Wellness & Pharmaceutical Division

1. Overview

The Company is undertaking a strategic expansion into the Integrated Health, Wellness, and Pharmaceutical Sector, featuring an extensive product portfolio,

This initiative aligns with the Company's long-term strategy of building a diversified, science-driven, and sustainable healthcare enterprise, catering to consumer, clinical, and institutional segments.

The expansion strengthens the Company's presence in Nutraceuticals, Cosmeceuticals, Pet Healthcare, and Generic Pharmaceuticals — all rapidly growing markets offering strong domestic and global potential.

2. Business Segments

a. Pet Care Division

The Pet Care Division focuses on functional nutrition, dermatology, and therapeutic wellness for companion animals.

Key Categories:

- **Functional Foods:** Advanced formulations supporting gut health, mobility, immunity, and overall wellness.
- **Nutritional Supplements:** Enriched with vitamins, minerals, amino acids, and probiotics for different breeds and life stages.
- **Cosmeceutical & Dermaceutical Line:** Products addressing allergies, skin infections, and coat enhancement, formulated with natural and clinical actives.
- **Durecal Therapeutic Range:** Disease-specific nutritional support for chronic and post-surgical recovery (hepatic, renal, and cardiac care).

Retail & E-Commerce Strategy:

The Company will launch a dedicated Pet Wellness Brand supported by a multi-channel model, including:

- A proprietary e-commerce platform for direct-to-consumer (D2C) sales,
- Integration with major marketplaces (Amazon, Flipkart, and niche pet platforms),
- Partnerships with veterinary clinics, grooming centers, and retail outlets, and
- Subscription-based models for regular wellness product delivery.

This ensures nationwide reach, digital scalability, and brand consistency across all customer touchpoints.

b. Human Care Division

The Human Care Division will address lifestyle-driven health challenges through nutritional, cosmeceutical, and dermatological solutions.

Key Categories:

- **Nutritional Products:** Functional foods and nutraceuticals focusing on immunity, metabolism, cardiac, and bone health.
- **Cosmeceuticals:** Skincare products that combine cosmetic appeal and pharmaceutical-grade performance using bioactive peptides, antioxidants, and natural extracts.

- Dermatological Range: Medicated formulations addressing acne, eczema, and scalp health — co-developed with dermatologists for clinical efficacy and compliance

c. Pharma Generics Division

The Pharma Generics Division represents the Company's entry into the regulated pharmaceutical market, focusing on cost-effective, high-quality generic formulations for both domestic and international markets.

Dosage Forms: Tablets, capsules, oral liquids, ointments, powders, and injectables — manufactured under GMP and WHO-compliant facilities.

3. Strategic Vision

The Company's mission is to evolve into a comprehensive, science-led, and ethically governed enterprise, bridging Nutrition, Dermatology, and Pharmaceuticals for both humans and animals.

4. Proposed Fund Allocation

Use of Funds	Approximate Allocation (%)
Brand Marketing & Distribution	35%
CAPEX (Plant, Machinery, Infrastructure)	5%
Formulation Development & R&D	5%
Working Capital	35%
Strategic & Statutory Reserves	15%
Contingency / Miscellaneous	5%
Total	100%

Countries targeted initial for expansion is as stated below.

Srilanka, Philippines, Nigeria, Togo, Ivory Coast, Zambia, Iran, UAE, Mali